J&J's immune disorder drug succeeds in mid and late-stage studies

Johnson & Johnson's (JNJ.N), experimental drug to treat two autoimmune disorders helped relieve symptoms when tested in adult patients in mid-stage and late-stage trials, the company said on Monday.